Changchun Deng, MD, PHD

Dr. Deng is an Assistant Professor of Clinical Medicine and Experimental Therapeutics at Columbia University Medical Center.

Dr. Deng attained his M.D. from Suzhou Medical College, China, and then earned his Ph.D. degree in Molecular, Cellular, and Developmental Biology from the University of Pittsburgh. Following his Ph.D. training he completed a post-doctoral research fellowship in Radiation and Cancer Biology at Stanford University. He then went on to complete a residency in Internal Medicine at the Lincoln Medical Center at Weill Cornell Medical College. Following his residency, he performed his Fellowship in Hematology and Oncology at the University of Texas Southwestern Medical Center, and New York Presbyterian Hospital /Columbia University Medical Center. After his fellowship training, Dr. Deng was appointed to the faculty at the New York University School of Medicine. Most recently, Dr. Deng was appointed Assistant Professor of Clinical Medicine and Experimental Therapeutics at the New York Presbyterian Hospital/Columbia University Medical Center.

Dr. Deng is board certified in Internal Medicine, Medical Oncology, and Hematology. He has well-rounded training in all aspects of Internal Medicine, and has substantial expertise in the management of hematological malignancies. Dr. Deng has published broadly on the treatment of mantle cell lymphoma, diffuse large B cell lymphoma, T- cell lymphoma, and Hodgkin lymphoma. He is currently the Principle Investigator (PI) of several promising clinical trials, including novel combinations based on discoveries from his own laboratory, with the aim to develop novel and more effective treatments for patients with lymphoid malignancies.

In addition to patient care and clinical research, Dr. Deng is also conducting in-depth studies into the pathogenesis of lymphoma and the discovery and development of new drugs for the treatment of lymphoma. His research has resulted in many publications in high impact scientific journals, and presentations at national meetings. Recently, his research focuses on developing new treatments for C-MYC, which is one of the most important oncogenes in lymphoma and is widely recognized as “undruggable”.  Dr. Deng has spearheaded a promising strategy that target C-MYC by silencing its translation in lymphoma cells. In addition, Dr. Deng has established substantial expertise in developing new treatments that the target PI3K and epigenetic pathways.